Here are the key details to know:
1. DEXYCU is the first FDA-approved single dose, sustained release intracameral steroid for the treatment of postoperative inflammation.
2. The code, J1095, will become effective Jan. 1, 2019, and will replace the previously issued C-code for DEXYCU (C9034) that became effective Oct. 1, 2018.
3. EyePoint Pharmaceuticals still retains transitional pass-through status for DEXYCU from CMS for approximately three years.
More articles on coding, billing and collections:
5 steps ASCs can follow to improve ASC billing performance
Maximize your 2018 reimbursements: Know your health plans, know your market, and stay on top of trends
3 essential elements, benefits to launching a bundled payment program in ASCs
